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Autonomy, at least in the  context of our framework  for patient decision making, 
is under siege.  The attack is coming 
from at least two quarters. Some 
believe that patients have taken the 
autonomy model too far, demanding 
certain treatments that physicians 
would not recommend. This has 
occurred in legal cases like Wanglie,1 
Gilgunn,2 and Baby K3 where 
physicians believed that continued 
life-sustaining treatment for the 
patient was “futile,” or medically 
inappropriate, and patients or their 
family members demanded continued 
treatment. But, it also occurs in other 
medical settings, for example, where 
pregnant women demand c-sections 
or assertive parents demand an 
antibiotic for their child’s sore throat. 
The second onslaught comes from 
a wholly different perspective, that 
patients are uncomfortable making 
complex medical treatment decisions 
for themselves, especially when their 
choices are fraught with uncertainty. 
These patients, or their family 
members, are overwhelmed by the 
information and the responsibility.
Most attention in the bioethical 
and medical literature has focused 
on the first of these assaults; I want 
to focus on the latter. There is 
considerable support for the view 
that patients who are ill and fragile 
may not want to make their own 
treatment decisions. In his book, 
The Practice of Autonomy: Patients, 
Doctors and Medical Decisions,4 law 
Professor Carl Schneider amasses 
considerable data on this point.  For 
example, he cites a study by Ende 
et al.,5 who presented 312 patients 
in a primary care clinic with a series 
of vignettes representing various 
levels of illness severity and asked 
them in each scenario, on a scale 
from 0 to 100, to indicate their desire 
for making their own treatment 
decision.  The mean score for the 
study population was 33.2, indicating 
that patient preferences for decision 
making were quite weak. In addition, 
they found that as patients were 
asked to consider increasingly severe 
illnesses and as they got older their 
desire to make decisions themselves 
declined.  
Schneider also presents data that 
patients are willing to cede some 
of their autonomy when they are 
incompetent, even if they have 
expressed preferences for or against 
various forms of treatment. He cites 
the work of Sehgal and colleagues6 
who asked 150 dialysis patients “how 
much leeway their physician and 
surrogate should have to override 
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NetwOrK News
MArYlAND HeAltH 
CAre etHICs 
COMMIttee 
NetwOrK (MHeCN)
MHECN is sponsoring a  panel discussion and dinner,  
Money & Medicine: Bedside Ethics 
of the Medical Marketplace, from 
4:30 p.m. to 7:15 p.m., at Greater 
Baltimore Medical Center on January 
30, 2007.  This symposium will 
provide an opportunity for health 
care providers and ethics committee 
members to explore the topic of 
health care cost as it relates to an 
individual clinical case. Speakers 
include Marion Danis, MD; Rebecca 
Elon, MD; MPH, Diane Hoffmann, 
JD, MS; and Jack Schwartz, JD. 
MHECN will offer its biannual 
basic ethics education conference 
for health care ethics committee 
members in the summer of 2007, 
most likely in June. This will be a 
one-day conference geared toward 
health care ethics committee 
members.
MHECN is pleased to announce 
that the Johns Hopkins Berman 
Institute of Bioethics (formerly 
the Phoebe R. Berman Bioethics 
Institute at Johns Hopkins) has joined 
MHECN as an affiliate member. 
We welcome their support and 
involvement.
Contact MHECN at (410) 706-4457; 
e-mail: MHECN@law.umaryland.
edu.
MHECN Program Coordinator:
 Anita J. Tarzian, PhD, RN.
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tHe MetrOPOlItAN
wAsHINGtON
BIOetHICs 
NetwOrK (MwBN)
MWBN members took  advantage of several local  ethics educational 
opportunities at Georgetown 
recently. It continues its guardian 
training sessions with the D.C. 
Superior Court Probate Division.
For more information about 
MWBN, contact Joan Lewis, 
Executive Director, 202-895-9408, 
e-mail jlewis@iona.org. 
rICHMOND 
BIOetHICs 
CONsOrtIUM (rBC)
At the VAST (Virginia  Association of Science  Teachers) conference 
in November, RBC presented 
information about a grant project 
to encourage science teachers 
to address bioethical issues in 
their classrooms. RBC is offering 
$500 "classroom mini-grants" for 
biology and life sciences teachers 
to introduce the topic of bioethics 
to students in grades 6-12.  RBC 
recently generated new mission and 
vision statements as a result of its 
strategic planning process.
For more information about RBC, 
contact  Gloria Taylor, RN, MA, 
CPTC, RBC President, at taylorgj@
unos.org.
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Choosing Paternalism?
Cont. from page 1
[their] advance directive if overriding 
were in [their] best interests.” The 
patients varied greatly in their 
responses: 39% said “no leeway;” 
19% said “a little leeway;” 11% 
said “a lot of leeway” and 31% said 
“complete leeway.”
Articles confirming this 
perspective have also appeared in 
the popular press. A little over a 
year ago, a New York Times article, 
entitled “Awash in Information, 
Patients Face a Lonely, Uncertain 
Road,”7 described the anguish and 
abandonment patients feel when 
forced to make difficult medical 
decisions. The article described the 
case of a 39 year old patient with 
ovarian cancer that had metastasized 
to her liver. She was asked to 
decide whether to undergo a novel 
chemotherapy regimen about which 
five oncologists disagreed. When she 
asked her doctor what she should 
do he said he didn’t know, that she 
would have to make the decision 
based on her own values. The patient, 
“bald, tumor-ridden and exhausted 
from chemotherapy was reeling. 
‘I’m not a doctor!’ she shouted, ‘I’m 
a criminal defense lawyer! How am 
I supposed to know?’” The story 
illustrates the frustration, anxiety, 
and loneliness of being a “modern 
patient” attempting to cope with 
medical uncertainty.  
When patients are competent, 
ideally they and their physicians 
engage in shared decision-making, 
where there is give and take between 
both and neither the autonomy nor 
the paternalism model dominates. 
However, once a patient lacks 
competency, the opportunity for 
shared decision-making may 
be gone (at least as between the 
patient and the physician). In those 
circumstances, how should we 
respond?
If we are persuaded by the studies 
and anecdotes indicating that at least 
some portion of our population is 
not comfortable with the “autonomy 
model,” should we change our legal 
framework for health care decision 
making, in particular our framework 
for making decisions about life-
sustaining treatment for patients 
lacking decision-making capacity? 
Certainly, we cannot abandon 
autonomy; for many people the 
autonomy model is still sacrosanct.  
Rather, we need a model that 
allows for flexibility – for both 
autonomy and paternalism. There 
are, however, obstacles to choosing 
paternalism once a patient lacks 
decision-making capacity. One 
reaction would be to give patients 
an option to “undermine” their own 
autonomy, i.e., to autonomously 
choose paternalism. At least one 
state, Alabama, has made it easier for 
patients to give up some autonomy 
by modifying the state’s advance 
directive form to allow patients to 
indicate whether they want their 
wishes strictly followed or prefer 
that their proxy do what he or she 
thinks is best, even if it means doing 
something different from what the 
patient has specified in the form.8 
The Maryland legislature recently 
made a similar change to its advance 
directive form.9
Another response would be to 
make it easier for patients to appoint 
their physician as their health care 
agent. Many states actually prohibit 
this, arguably due to concerns about 
physician paternalism and possible 
conflicts of interest.10  Ironically, 
these laws replace physician 
paternalism with state paternalism.11 
In New York, for example, health 
care proxy instructions provide that 
you can appoint your physician as 
your proxy but then he/she cannot 
also be your treating physician.12 
In Maryland, a physician can be 
appointed as a health care agent 
Cont. on page 10
MARyLAND PATIENTS GIvEN ADvANCE 
DIRECTIvE FLExIBILITy
During the 2006 Legislative Session, the Maryland General Assembly 
passed several amendments to the Health Care Decisions Act. Among those 
changes was a provision in the advance directive form allowing patients to 
specify how strictly they want their stated preferences followed. The model 
form includes a provision allowing the individual completing the form to 
choose one of the following options:
1.  I realize I cannot foresee everything that might happen after I can no 
longer decide for myself. My stated preferences are meant to guide whoever 
is making decisions on my behalf and my health care providers, but I 
authorize them to be flexible in applying these statements if they feel that 
doing so would be in my best interest.
2.  I realize I cannot foresee everything that might happen after I can no 
longer decide for myself. Still, I want whoever is making decisions on my 
behalf and my health care providers to follow my stated preferences exactly 
as written, even if they think that some alternative is better.
4  Mid-Atlantic Ethics Committee Newsletter
I am not a classical philosopher by trade or training, but a medical  oncologist and medical school 
professor who trained in clinical 
medical ethics. One of the most 
compelling reasons for such training, 
which was not regularly offered in 
medical school in the 1980’s, was 
to be able to ethically navigate my 
patients and myself through the 
complex challenges that arise when 
enrolling a patient with cancer in a 
clinical trial. 
It is helpful to understand that 
there are four phases of clinical 
trials, each with its own particular 
set of ethical challenges. But the 
Phase I trial is most vexing to a host 
of bioethicists and researchers alike. 
Phase I cancer therapy trials 
involve the use of an experimental 
agent or experimental use 
of conventional agents, or a 
combination of the two. These 
trials are aimed at cancers that have 
become resistant to conventional 
agents, or those for which there 
is minimal effective treatment or 
cure, such as advanced melanoma, 
and cancers of the kidney, liver/gall 
bladder, and brain, among others. 
ClINICAl CANCer reseArCH: CAN tHe
PHAse I trIAl eVer Be etHICAl?
The experimental agents have had 
some success in preclinical, usually 
animal experiments, so they are 
now being tried in humans. The 
chance they will shrink or at least 
stabilize the cancer is somewhere 
between 5 and 40%. 
The primary goal of the Phase I 
trial is to test the experimental agent 
for side effects and dose limiting 
toxicity, with efficacy against the 
cancer a distant secondary goal.  
Phase I trials are not limited to 
cancer research, and the same 
principles may be generally applied 
when researching other diseases. 
It is the closest one gets to the 
patient being, as many of mine 
have correctly said, “a guinea pig.” 
Despite the fact that patients, or 
subjects, as they are called when 
they enter a clinical trial, are told 
that the goal is not therapeutic, 
surveys have shown that many 
patients believe the reason they are 
participating in the Phase I trial is to 
cure their cancer.
Testing new therapies on patients 
to see how toxic they are … does 
that sound ethical? It has not 
been that long since the Tuskegee 
Syphilis Study, Willowbrook 
hepatitis experiments or the 
atrocities performed in the name of 
science by the Nazis during WWII. 
Safeguards, beginning  with the 
Belmont Report and the Nuremburg 
Code, and creation of institutional 
review boards with oversight of 
the protection of human subjects, 
have been placed to prevent such 
practices from ever occurring again. 
With those protections, toxicities 
are monitored very closely during 
Phase I trials, not only since that 
is the focus of the study, but also 
as a way to protect the patient 
from undue harm. Patients who are 
considered too vulnerable, such as 
those who are mentally challenged, 
prisoners, and others, are excluded 
from the studies. And consent forms 
are extensive and written to make 
sure that potential study subjects 
receive the most comprehensive 
information possible (which may 
actually be a drawback, in the form 
of information overload). 
Those who feel that phase I 
studies may be conducted ethically 
use two main arguments; one, that 
if patients give their consent, after 
being informed extensively of the 
risks, benefits and the purpose of 
the trial, then it is their autonomous 
decision to do so. Secondly, it is 
arguably ethical to offer possible 
treatments that may slow the 
cancer and may also advance the 
science of cancer treatment overall. 
Toxicity and study outcomes 
are carefully monitored, and the 
study is discontinued if there is 
excess toxicity or excess mortality 
attributable to the agents being 
studied.  
On the con side, there are 
arguments that informed consent 
is not really possible in these 
circumstances because the patients 
are vulnerable and desperate, 
frightened by the specter of 
advancing disease. In addition, the 
complex nature of both the study 
designs and the treatment itself does 
not allow for full understanding 
by most patients, even with the 
most thorough disclosure. After all, 
thorough disclosure does not equal 
thorough understanding. 
There are also competing interests 
for the physician-scientist—the 
patient under his or her care and 
that of scientific as well as personal 
professional advancement. The 
conflict between patient care and 
Cont. on page 10
Although MHECN does not focus 
specifically on research ethics, there 
may be times when a physician is put 
in the role of advising a patient as 
to whether he or she should enroll 
in a Phase I clinical trial. This 
article, by Laurie Lyckholm, an 
Associate Professor and Program 
Director of Hematology/Oncology 
and Palliative Medicine at Virginia 
Commonwealth University School 
of Medicine, explores this topic 
and provides a helpful framework 
for physicians confronted with this 
question.
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According to the American  Society for Bioethics and  Humanities’ Core 
Competencies for Health Care 
Ethics Consultation (1998), at 
least one person in your facility’s 
ethics committee (EC) should have 
advanced expertise in each of these 
areas: 
• Moral reasoning and ethical 
theory
• Common bioethical issues 
and concepts
• Health care systems
• Clinical context
• Local health care 
organization’s policies, 
including those on:
	Advance Directives
	Organ Donation
	Goals of Care
	Patients with Long Term 
   Stays
	Patient Consent
	Ethics Committee Access
	HIV Testing
	Interdisciplinary 
Collegiality
	Reproductive Services
•Cultural and religious beliefs 
of those served by the facility
•Relevant codes of ethics and 
professional conduct guidelines
•Relevant health law
In addition, Anita Catlin, DNSc, 
FNP, FAAN, Ethics Consultant and 
Associate Professor of Nursing 
at Sonoma State University in 
California, recommends the 
Is YOUr etHICs COMMIttee COMPeteNt tO 
CONsUlt? wHAt Are BeNCHMArKs Of sUCCess?
following benchmarks to measure 
the competence of your committee 
(Catlin, 2006, p. 9):
• Ethics should be proactive, not 
reactive. The EC should work 
to create or improve policy that 
might mitigate continual response 
to individual dilemmas.
• The outcomes of the ethics 
committee should be translated 
into demonstrable outcomes.
• The EC has representation from 
all constituencies in the hospital, 
with co-chairs representing the 
largest facility constituency (e.g., 
nursing). 
• The EC is well trained by a 
leader in ethics who has received 
formal ethics education. 
• EC members are known to 
facility staff, are trained in 
consultation, and are available 
for immediate discussions of 
minor issues, and can call for a 
full committee consultation when 
needed. 
• There is a standard recorded 
format for the ethics consultation. 
The form is kept and used 
for data collection, trend 
identification, and educational 
purposes.  
• Members of the facility know 
how to contact the EC, and do so. 
There are materials available on 
the units for reference.
• Ethics rounds are made on the 
various shifts. There is an ethics 
training binder on every unit.
• Members of the EC belong to 
and attend the annual meeting 
of the American Society for 
Bioethics and Humanities. Each 
member has a copy of the Core 
Competencies for Health Care 
Ethics Consultation. 
• Members of the EC receive 
and read health care ethics 
journals, such as the Journal of 
Clinical Ethics; the Hastings 
Center Report, HEC Forum, 
or the Cambridge Quarterly of 
Healthcare Ethics.
• Physician members have 
received End-of-Life Physician 
Education Consortium (EPEC), 
or comparable, training.
• Nurse members have received 
End-of-Life Nursing Education 
Consortium (ELNEC), or 
comparable, training.
• Members of the staff are aware 
of the Nursing and Medical 
Codes of Ethics and Patient’s 
Bill of Rights, and care is 
delivered accordingly.
References:
Catlin, A. (2006), Plan to Bring Ethics 
Committee to Magnet Standards, Submitted to 
Kaiser Santa Rosa Organization, Santa Rosa, 
California, September 15, 2006.
American Society of Bioethics and 
Humanities (1998), Core Competencies for 
Health Care Ethics Consultation. Glenview, 
Illinois: American Society of Bioethics and 
Humanities. Order online at www.asbh.org.
American Medical Association (AMA) 
Council on Ethical and Judicial Affairs 
(2006), Code of Medical Ethics 2006-2007: 
Current Opinions with Annotations (Code 
of Medical Ethics). American Medical 
Association.
American Nurses Association (2001), Nursing 
Code of Ethics with Interpretive Statements.
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fOCUs ON  
tHe CeNter fOr etHICs 
At tHe wAsHINGtON HOsPItAl CeNter
The Center for Ethics at the  Washington Hospital Center,  founded by Dr. John Lynch, is 
credited with being one of the oldest 
hospital ethics programs in the 
country. It evolved from an ethics 
committee established in 1982 to a 
program housed in the Hospital’s 
Department of Pastoral Care, and 
then developed into a separate 
department in 1992. Its current 
director is Nneka Mokwunye, a PhD 
candidate at Howard University. 
Two other bioethicists on staff are 
Evan DeRenzo, PhD and Daria 
Grayer, MA. Dr. Lynch is still an 
active member of the Center and is 
the current Chair of the Hospital’s 
ethics committee.
The Center provides consultations 
in clinical and research practice, 
and also coordinates  continuing 
education programs in bioethics, 
develops and critiques institutional 
hospital policy, and develops and 
implements independent research on 
biomedical issues. The Center runs 
a 35-member bioethics committee 
that has three subcommittees: 
policy, education, and consultation. 
A new venture for the Center is 
the publication of The Journal of 
Everyday Clinical Ethics.  The 
Journal is scheduled to be released 
January 2007. (For further details on 
submissions please email ethics@
medstar.net.) 
The Center’s mission is to 
“develop, promote and maintain 
the highest standards in ethical 
knowledge and awareness in all 
aspects of clinical practice.”  In 
October, as part of its own education 
mission, the Center hosted a 
Bioethics Awareness Week (October 
16-20, 2006). Events included 
opportunities to meet the members 
of the ethics committee and discuss 
bioethics topics such as medical 
futility; an advance directive fair 
and information seminar; women’s 
awareness workshops; “breakfast 
with bioethics” to discuss clinical 
ethics case studies; and “ask the 
ethicist” sessions where staff 
and community members could 
bring their own ethical issues for 
clarification or discussion. During 
the advance directive fair the Center 
staff assisted  over 150 participants 
in  completing advance directives 
and disseminated  numerous 
information packets for participants 
to give to their family members and 
friends. 
 The week long educational 
program included a focus on 
HIV awareness and prevention 
specifically on disclosure of HIV 
positive mothers to their partners. 
The goal was to help these mothers 
obtain the necessary assistance for 
protecting their babies from HIV 
transmission. “Breakfast with 
Bioethics” and “Ask the Ethicist” 
sessions were a time for staff to 
ask any questions they had about 
these issues, in particular. The 
ability to discuss one-on-one with 
the bioethicists gave the staff a 
mechanism to release any moral 
distress they were feeling and 
find comfort in knowing that their 
concerns were being addressed. 
The Center will be holding 
Bioethics Awareness Week 
annually.
Has YOUR facility instituted a 
special program or educational 
endeavor in bioethics that you 
would like to share? Let us know 
by emailing us at MHECN@law.
umaryland.edu, or calling (410) 
706-4457.
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One of the regular features of the 
Newsletter is the presentation of 
a case considered by an ethics 
committee and an analysis of the 
ethical issues involved.  Readers are 
both encouraged to comment on the 
case or analysis and to submit other 
cases that their ethics committee has 
dealt with.  In all cases, identifying 
information about patients and 
others in the case should only 
be provided with the permission 
of the patient.  Unless otherwise 
indicated, our policy is not to 
identify the submitter or institution.  
Cases and comments should be sent to 
MHECN@law.umaryland.edu, or 
MHECN, the Law & Health Care 
Program, University of Maryland 
School of Law, 500 W. Baltimore St., 
Baltimore, MD 21201.
CAse stUDY frOM 
A D.C. HOsPItAl
Ms. Casey is a 32 year old  woman who delivered a full term infant at a D.C. 
hospital. As she is HIV positive, 
the team begins teaching her about 
the antiretroviral regimen her infant 
will be sent home with. Ms. Casey 
discloses to her physician that her 
husband does not know that she 
is HIV positive, and she does not 
intend to tell him. There is reason 
to believe that Ms. Casey does 
not intend to give her infant the 
antiretroviral drugs prescribed, and 
may not be taking antiretrovirals 
herself, for fear her husband will 
find out about her HIV status. The 
CAse PreseNtAtION
himself from any further 
exposure to HIV,
• beneficence towards any other 
person who the father may infect 
if he is HIV positive, due to not 
knowing his own HIV status,
• beneficence towards the baby 
in providing necessary medical 
interventions to prevent  HIV 
infection,
• nonmaleficence to the mother by 
avoiding harm that would ensue 
if her privacy and confidentiality 
were violated if her HIV status 
were to be disclosed,
• nonmaleficence to the father by 
avoiding harm that might ensue 
if he were not informed about 
his wife’s HIV status and his 
own risk of being infected, and 
• nonmaleficence toward the baby 
by preventing HIV transmission 
through preventive treatments, 
which is less likely to happen if 
both parents are not informed 
of the medical appropriateness 
of the antiretroviral drugs for 
prevention of transmission. 
It is the ethical duty of the hospital 
to provide appropriate care for its 
patients. In this case, the baby and 
the mother are both patients of the 
hospital. In an effort to protect the 
baby, the physicians have the ethical 
duty to inform both parents of the 
risks of exposure to HIV and the 
therapies needed to minimize or 
eliminate transmission. If, in having 
physician tries to convince Ms. 
Casey of the importance of taking 
antiretroviral medications and of 
telling her husband about her HIV 
status, but she is adamantly opposed 
to doing so. She tells the physician 
and nurse involved in her care that if 
someone informs her husband about 
her HIV status, she will sue for 
privacy violation. The nurse requests 
an ethics consult. She is concerned 
about the rights of the husband and 
the welfare of her patient's infant. 
resPONse frOM A 
BIOetHICIst
AND etHICs 
CONsUltANt
The ethical dilemma of this case rests on the collision of the principles of autonomy, 
beneficence, and nonmaleficence.  
These principles are at play in the 
following ways:
• the autonomy of the mother 
to request that her HIV status 
remain private and confidential,
• the autonomy of the father to 
have any relevant information 
that directly relates to his well 
being presented to him,
• beneficence towards the mother 
to protect her from the negative 
consequences of her HIV status 
being divulged,
• beneficence towards the father 
by allowing him to protect 
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this conversation, the father deduces 
that the HIV exposure comes from 
his wife, then that it is a side effect 
of the informed consent process. 
Ethically, there is a strong 
argument that the patient has a moral 
obligation to inform her husband 
about her HIV status. The physician 
can do his or her best to convince the 
patient to do so. However, opinions 
differ about whether a physician’s 
primary duty is to protect the 
patient-provider relationship by not 
breaching a patient’s trust (i.e., by 
informing a sexual partner about 
positive HIV status), or to protect 
a third party who may be at risk of 
harm. For example, some argue that 
more harm may come by requiring 
physicians to breach patient 
confidence in such situations, since 
this may erode patient-provider 
trust and lead to patients avoiding 
medical care. 
While clinicians are obligated to 
warn others of known direct harms 
(for example, a homicidal patient 
divulges a plan to his psychologist 
to kill his girlfriend, as in the famous 
Tarasoff case), there are differing 
opinions about whether or not 
Cont. from page 7
divulging a positive HIV status to 
a current or former sexual partner 
constitutes direct harm. States 
have different laws about clinician 
disclosures in such situations. In 
the District of Columbia (D.C.), 
the physician cannot inform the 
patient's husband that he has been 
exposed to HIV or suggest that 
he be tested and protect himself 
from further exposure. (In contrast, 
Maryland law allows, but does 
not obligate, a physician to make 
such a disclosure.) However, D.C. 
law allows the physician to inform 
a child’s father of all relevant 
information regarding the welfare 
of the child, and this supersedes the 
right of the mother to keep her HIV 
status private. 
The physician should inform the 
mother that relevant information 
to provide appropriate care for 
the baby (including the need for 
ART medication to prevent HIV 
transmission) will be shared with 
her husband. Once the baby is born, 
all information relevant to provide 
appropriate treatment for the baby 
must be divulged to both parents. 
The mother may sue the hospital 
for violating her right to privacy. 
That is a price the hospital has to 
pay to fulfill its ethical obligation 
to provide adequate care to the 
baby, which in this case trumps the 
obligation to protect the mother’s 
privacy regarding her HIV status. 
As the ethics consultant for the case, 
my recommendation would be to 
inform the mother that the health 
care team will provide all relevant 
medical information about the care 
of the infant to both parents, and 
the baby will not be discharged 
until this conversation has taken 
place and there is agreement to 
follow the regimen to minimize HIV 
transmission. I would have social 
services continue to follow the case 
and child protective services keep 
an eye on the situation to make sure 
the baby is getting the necessary 
treatments.
Nneka Mokwunye
Ph.D. Candidate, M.A.
Director, Center for Ethics
Washington Hospital Center
CAse PreseNtAtION
EDUCATIONAL OPPORTUNITy! -Class Ethics Course at  
INOvA Health System, Falls Church, vA
Thursday, February  , 007  
Ethics in Everyday Clinical Practice
Wednesday, April 11, 007  
Current Controversies in Healthcare Ethics
 
Friday, May 11, 007 
Ethical & Psychosocial Management of the Patient and Family Identified as Difficult 
For more information, contact Patti O’Donnell, PhD, Director, Center for Ethics,  
Inova Health System at 703-321-2658 (phone) or patricia.odonnell@inova.com.  
To register, call Inova Teleservices at 703-205-8384. 
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resPONse frOM A 
NUrse AttOrNeY
This case is about the welfare of the child. The mother’s  statements have given rise 
to a reasonable probability that the 
child will not get the necessary 
medications and that universal 
precautions will not be observed. 
Immediate and life-threatening harm 
to the child is likely. 
If I were hospital counsel I 
would call the Emergency Judge 
and Petition for the appointment 
of a Temporary Guardian of the 
Child. I would allege parental 
neglect.  An immediate hearing 
on the Emergency Petition would 
be scheduled at the hospital. The 
parents would attend the hearing 
during which only the child’s 
medical status would be discussed. 
Any available lab values or other 
information about the child which 
would justify the need for the 
antiviral regimen would be revealed. 
The doctors may ultimately just 
state that they have reason to believe 
the child has had a significant HIV 
exposure. The husband is likely to 
deduce the source of the child’s need 
for antiretrovirals without being 
directly told that the wife is HIV 
positive. If he should ask outright, 
the hospital staff could suggest that 
he discuss this with his wife. 
After the disclosure of the 
child’s status (and most likely the 
mother’s HIV positive status), 
there may be no need for further 
court intervention. The mother 
or father may agree to administer 
the medications. If the mother is 
uncooperative and continues to resist 
medicating the child, taking her own 
medications and observing universal 
precautions,  I am confident that 
a D.C. judge would appoint a 
Guardian of the child and order the 
antiretroviral treatment on a parens 
patriae theory.  The husband/father 
could be appointed depending on his 
conduct at the hearing. The judge 
might order ongoing intervention 
by a child welfare agency.  In 
any event, this family is going to 
need a lot of support and ongoing 
monitoring once the child’s medical 
status is revealed. 
An emergency Petition is exactly 
the action I have taken in several 
cases in which the parent of a minor 
child/infant has refused blood 
transfusions for religious reasons. 
In those cases the parents had an 
arguably valid reason for refusing 
the treatment. Here, the mother’s 
reason is somewhat understandable, 
but is secondary to considerations 
of the child’s welfare. If she is 
concerned about domestic violence 
or abandonment of financial support 
by the spouse, the wife should be 
offered access to any available 
resources. The husband will discover 
her HIV positive status  sooner 
or later. This information is best 
delivered in the relative safety of 
the hospital with readily available 
information and support for the 
family. 
The father of the child has a right 
to know about the child’s medical 
status and a right to protect himself.  
The hospital has an ethical duty to 
advise him of the child’s medical 
status and the need to use universal 
precautions when caring for the 
child, both for the child’s welfare as 
well as his own. Unless the hospital 
provides this information to both 
parents, the child cannot be safely 
discharged. 
The hospital risks the wife’s 
lawsuit for invasion of privacy. 
However, this risk is far less than 
the risk to both the welfare of the 
child and the husband.  The child 
is likely to sustain harm if deprived 
of reasonable medical treatment 
and could sue the hospital.   The 
hospital has no rational basis to 
permit withholding of information 
about the child’s medical needs from 
the father. One parent has no greater 
rights to control this information 
than the other parent, assuming there 
are no questions about paternity. 
Andrea Sloan, R.N., Esq.
Private Practice
CAse PreseNtAtION
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Clinical Cancer research
Cont. from page 4
the advancement of knowledge is 
one that I personally find daunting 
at times, as I find it difficult to tell a 
patient that they will be  “used” to 
evaluate toxicity and dose limitations; 
however Phase I trials have resulted 
in effective treatments and wondrous 
advances in cancer care. The bottom 
line, however, is that the person in 
front of me is, and will always be, 
front-and-center my primary interest.
So, how can this dilemma be 
resolved? The first premise must be 
that there is no way around it: Phase 
I trials must be performed in order 
to make cancer treatment advances 
for the next generation. There must 
but only if he/she is not the owner, 
operator, or employee of a health 
care facility where the patient is 
receiving care, unless the physician 
would also  qualify as a surrogate 
decision-maker under the law.13 
Whether or not we should loosen 
our laws to allow for this option 
raises normative questions about 
whether physicians should be given 
the authority to both treat and act as 
agent. 
Unfortunately, our current 
framework for health care decision 
making seems to be one in which 
we expect that one size will fit 
all.  In the 1960s, we rejected the 
paternalism model and adopted 
autonomy. Perhaps, at least in the 
context of decision-making for 
patients who lack capacity, we 
need a scheme that allows for both 
— permitting the patient to choose 
autonomy or paternalism.
Endnotes
1 In re  Conservatorship of Wanglie, 
No. PX-91-283 (Minn. Dict. Ct. 
Choosing Paternalism?
Cont. from page 3
with advanced cancer must be 
informed of the alternative to clinical 
trials, which is supportive care that 
may translate to better quality of 
life, and they must be told clearly 
that they have a choice in the matter. 
Finally, the physician-scientists 
must try to resolve their conflicts of 
interest in favor of the person in front 
of them—their patient. 
Laurie Lyckholm, M.D.
Associate Professor and
Program Director
Hematology/Oncology and
Palliative Medicine
Virginia Commonwealth University 
School of Medicine
Hennepin Co., June 28, 1991).
2 Gilgunn v. Mass. Gen. Hosp., No. 92-
4820 (Mass. Super. Ct., Apr. 21, 1995).
3 In re Baby “K”, 16 F.3d 590 (4th Cir. 
1994).
4 Carl E. SChnEidEr, ThE PraCTiCE 
of auTonomy: PaTiEnTS, doCTorS, and 
mEdiCal dECiSionS (1998).
5 Id.  at 36 (citing Jack Ende et al., 
Measuring Patients’ Desire for Autonomy: 
Decision Making and Information-Seeking 
Preferences Among Medical Patients, 4 J. 
GEn. inTErnal mEd. 23 (1989)).
6 Id. at 42 (citing Ashwini Sehgal et al., 
How Strictly Do Dialysis Patients Want 
Their Advance Directives Followed?, 267 
J. am. mEd. aSS’n 59 (1992)).
7 Jan Hoffman, Awash in Information, 
Patients Face a Lonely, Uncertain Road, 
n.y. TimES, Aug. 14, 2005, § 1, at 1.
8 ala. CodE § 22-8A-4(h) (LexisNexis 
Supp. 2005). 
9 S. 369, 2006 Leg., 421st Sess. (Md.  
2006). The Department of Veterans Affairs 
is also revising its Advance Directive 
Form to include a provision that would 
allow patients to specify how strictly they 
want their preferences followed. Personal 
communication from the VHA National 
Center for Ethics in Health Care, March 
31, 2006. 
10 See Arti Rai, Mark Siegler, & 
John Lantos, The Physician as a 
Health Care Proxy, haSTinGS CTr. 
rEP., Sept./Oct. 1999, at 14. 
11 Id. at 16.
12 n.y. Pub. hEalTh law § 
2980(3)(c) (McKinney 2002).
13 md hEalTh GEn Code Ann § 5-
602(b)(2) (2006).
Reprinted with permission from 
the Lahey Clinic Newsletter: 
Medical Ethics, Vol. 13, Issue 
2 (Spring 2006), and available 
online at the Hastings Center
Bioethics Forum, 
http://www.bioethicsforum.org/
be a paradigm change that informed 
consent is not the ethical litmus test 
of the Phase I trial. There is no one 
true ethical rationalization for the 
Phase I trial, but rather a simple set of 
criteria that, if followed, will assist in 
rendering ethical the Phase I trial: (1) 
those designing and administering the 
study do so as carefully as possible so 
as to minimize harm and maximize 
efficacy; (2) those providing care and 
information for the study subject do 
their very best to inform them that 
they are being studied for side effects 
and toxicity primarily, and that the 
likelihood of their cancer responding 
to the treatment is less than 50%, with 
cure nearly impossible; (3) patients 
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CAleNDAr Of eVeNts
JANUARy
 (9:00 a.m.)  Current Challenges in Research Ethics. Sponsored by the SouthEastern Pennsylvania 
Consortium for Higher Education. Speaker: Arthur Caplan, Ph.D. Holy Family University, 9801 
Frankford Ave., Philadelphia, PA. Contact: (215) 572-8543, or register online at www.sepche.org.
 (7:00 p.m. – 9:00 p.m.) (free)  Why You Should Care About Research on Humans in Developing 
Countries. Speaker Nancy Kass, Sc.D. Sponsored by the Johns Hopkins Berman Bioethics Institute, 
“Grounds for Discussion.” Evergreen Coffee House at 501 West Cold Spring Lane, Baltimore. 
For more information on this event, please visit www.hopkinsmedicine.org/bioethics/events/
GrandRounds.pdf, or contact Stephanie Davis at stdavis@jhsph.edu or 410-516-8570.  RSVP 
Requested.
5 1 Noon (free)  Grand Rounds: Bioethics, Genetic Testing and Genomic Medicine. Sponsored by 
the Shady Grove Adventist Hospital Ethics Committee. Oak Room, Weinschel Education Center, 
Shady Grove Adventist Hospital, Rockville, MD. Contact: paul@vannice.com.
6 (:00 a.m. – 4:0 p.m.)  The Future of Hospital Ethics. The Orange Tree Golf Resort, 10601 N. 
56th St., Scottsdale, AZ. Contact: 602-445-4356, e-mail edservices@azhha.org, or visit www.azhha.
org/public/education and click on “Program Calendar.”
 
0 (4:0 p.m. – 7:15 p.m.)  Money and Medicine: Bedside Ethics of the Medical Marketplace. Co-
sponsored by the Maryland Health Care Ethics Committee Network at the University of Maryland 
School of Law, the Health Facilities Association of Maryland, and Med-Chi. Greater Baltimore 
Medical Center (GBMC), Towson, Maryland. For more information, visit www.law.umaryland.edu/
mhecn, call Lu Ann Marshall at (410) 706-4128, or  MHECN at (410) 706-4457, e-mail MHECN@
law.umaryland.edu. 
FEBRUARy
  (7:0 a.m.)   Giving and Receiving Bad News, The Sister Margaret James Lecture. Speaker Rhonda 
Fishel, MD. St. Agnes Hospital, 900 Caton Avenue, Baltimore, MD. Registration and breakfast at 
7:00 a.m. in the Alagia Auditorium.  Lecture at 7:30 a.m.  RSVP to Carol Webb at 410-368-3412 by 
February 1.
1 (7:00 p.m. – :00 p.m., reception to follow)  “Medicare Matters: Is a Social Contract Possible 
in Health Care?” Christine K. Cassell, MD, MACP.  The Fourth Annual John Collins Harvey 
Lectureship, Leavey Conference Center, Georgetown University.  Contact and RSVP: 202-687-
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